Experimental CAR-T therapy targets tough lymphoma in early trial
NCT ID NCT07382817
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new treatment called JV-394 for people with T/NK cell lymphoma that has come back or not responded to standard therapy. JV-394 is made from a patient's own immune cells, which are modified to attack cancer cells. The main goal is to find a safe dose and watch for side effects in 33 adult participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JV-394 (a type of CAR-T cell therapy made from the patient's own immune cells)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat T/NK cell lymphoma.
What could go wrong
This is a very early Phase 1 trial with only 33 participants, so it may not work or could cause serious side effects. The therapy is still experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact